Add to ORKGAlzheimer's disease biomarkers are important for early diagnosis in routine clinical practice and research. Three core CSF biomarkers for the diagnosis of Alzheimer's disease (Aβ42, T-tau, and P-tau) have been assessed in numerous studies, and several other Alzheimer's disease markers are emerging in the literature. However, there have been no comprehensive meta-analyses of their diagnostic performance. We systematically reviewed the literature for 15 biomarkers in both CSF and blood to assess which of these were most altered in Alzheimer's disease
Background: CSF biomarkers’ performance for predicting conversion from mild cognitive impairment (MC...
Cerebrospinal fluid (CSF) biomarkers may be used to identify and monitor pathological processes in t...
Alzheimer's disease (AD) characterization has progressed from being indexed using clinical symptomat...
The diagnostic guidelines of Alzheimer's disease (AD) have recently been updated to include brain im...
Amyloid based hypothesis led to develop biomarkers oriented diagnosis of neurodegenerative dementias...
Research progress has provided detailed understanding of the molecular pathogenesis of Alzheimer dis...
Background: Current research criteria for Alzheimer’s disease (AD) include Cerebrospinal Fluid (CSF)...
The aim of this study was to test the diagnostic value of cerebrospinal fluid (CSF) beta-amyloid (Aβ...
The aim of this study was to test the diagnostic value of cerebrospinal fluid (CSF) beta-amyloid (Aβ...
The diagnosis of AD is still largely based on exclusion criteria of secondary causes and other forms...
ABSTRACT Introduction: Several studies have been conducted in order to validate cerebrospinal fluid...
The CSF biomarkers tau and Aβ42 can identify patients with AD, even during the preclinical stages. H...
Alzheimer’s disease (AD) represents a major public health concern and has been identified as a resea...
Alzheimer disease (AD) is a neurodegenerative disorder characterized by significant cognitive defici...
Cerebrospinal fluid (CSF) samples from 21 patients with a clinical diagnosis of Alzheimer's disease ...
Background: CSF biomarkers’ performance for predicting conversion from mild cognitive impairment (MC...
Cerebrospinal fluid (CSF) biomarkers may be used to identify and monitor pathological processes in t...
Alzheimer's disease (AD) characterization has progressed from being indexed using clinical symptomat...
The diagnostic guidelines of Alzheimer's disease (AD) have recently been updated to include brain im...
Amyloid based hypothesis led to develop biomarkers oriented diagnosis of neurodegenerative dementias...
Research progress has provided detailed understanding of the molecular pathogenesis of Alzheimer dis...
Background: Current research criteria for Alzheimer’s disease (AD) include Cerebrospinal Fluid (CSF)...
The aim of this study was to test the diagnostic value of cerebrospinal fluid (CSF) beta-amyloid (Aβ...
The aim of this study was to test the diagnostic value of cerebrospinal fluid (CSF) beta-amyloid (Aβ...
The diagnosis of AD is still largely based on exclusion criteria of secondary causes and other forms...
ABSTRACT Introduction: Several studies have been conducted in order to validate cerebrospinal fluid...
The CSF biomarkers tau and Aβ42 can identify patients with AD, even during the preclinical stages. H...
Alzheimer’s disease (AD) represents a major public health concern and has been identified as a resea...
Alzheimer disease (AD) is a neurodegenerative disorder characterized by significant cognitive defici...
Cerebrospinal fluid (CSF) samples from 21 patients with a clinical diagnosis of Alzheimer's disease ...
Background: CSF biomarkers’ performance for predicting conversion from mild cognitive impairment (MC...
Cerebrospinal fluid (CSF) biomarkers may be used to identify and monitor pathological processes in t...
Alzheimer's disease (AD) characterization has progressed from being indexed using clinical symptomat...